Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
Noe B Mercado, Roland Zahn, Frank Wegmann, Carolin Loos, Abishek Chandrashekar, Jingyou Yu, Jinyan Liu, Lauren Peter, Katherine McMahan, Lisa H Tostanoski, Xuan He, David R Martinez, Lucy Rutten, Rinke Bos, Danielle van Manen, Jort Vellinga, Jerome Custers, Johannes P Langedijk, Ted Kwaks, Mark J G Bakkers, David Zuijdgeest, Sietske K Rosendahl Huber, Caroline Atyeo, Stephanie Fischinger, John S Burke, Jared Feldman, Blake M Hauser, Timothy M Caradonna, Esther A Bondzie, Gabriel Dagotto, Makda S Gebre, Emily Hoffman, Catherine Jacob-Dolan, Marinela Kirilova, Zhenfeng Li, Zijin Lin, Shant H Mahrokhian, Lori F Maxfield, Felix Nampanya, Ramya Nityanandam, Joseph P Nkolola, Shivani Patel, John D Ventura, Kaylee Verrington, Huahua Wan, Laurent Pessaint, Alex Van Ry, Kelvin Blade, Amanda Strasbaugh, Mehtap Cabus, Renita Brown, Anthony Cook, Serge Zouantchangadou, Elyse Teow, Hanne Andersen, Mark G Lewis, Yongfei Cai, Bing Chen, Aaron G Schmidt, R Keith Reeves, Ralph S Baric, Douglas A Lauffenburger, Galit Alter, Paul Stoffels, Mathai Mammen, Johan Van Hoof, Hanneke Schuitemaker, Dan H Barouch, Noe B Mercado, Roland Zahn, Frank Wegmann, Carolin Loos, Abishek Chandrashekar, Jingyou Yu, Jinyan Liu, Lauren Peter, Katherine McMahan, Lisa H Tostanoski, Xuan He, David R Martinez, Lucy Rutten, Rinke Bos, Danielle van Manen, Jort Vellinga, Jerome Custers, Johannes P Langedijk, Ted Kwaks, Mark J G Bakkers, David Zuijdgeest, Sietske K Rosendahl Huber, Caroline Atyeo, Stephanie Fischinger, John S Burke, Jared Feldman, Blake M Hauser, Timothy M Caradonna, Esther A Bondzie, Gabriel Dagotto, Makda S Gebre, Emily Hoffman, Catherine Jacob-Dolan, Marinela Kirilova, Zhenfeng Li, Zijin Lin, Shant H Mahrokhian, Lori F Maxfield, Felix Nampanya, Ramya Nityanandam, Joseph P Nkolola, Shivani Patel, John D Ventura, Kaylee Verrington, Huahua Wan, Laurent Pessaint, Alex Van Ry, Kelvin Blade, Amanda Strasbaugh, Mehtap Cabus, Renita Brown, Anthony Cook, Serge Zouantchangadou, Elyse Teow, Hanne Andersen, Mark G Lewis, Yongfei Cai, Bing Chen, Aaron G Schmidt, R Keith Reeves, Ralph S Baric, Douglas A Lauffenburger, Galit Alter, Paul Stoffels, Mathai Mammen, Johan Van Hoof, Hanneke Schuitemaker, Dan H Barouch
Abstract
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic1-8. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in non-human primates. Fifty-two rhesus macaques (Macaca mulatta) were immunized with Ad26 vectors that encoded S variants or sham control, and then challenged with SARS-CoV-2 by the intranasal and intratracheal routes9,10. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs after SARS-CoV-2 challenge. Titres of vaccine-elicited neutralizing antibodies correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in non-human primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.
Figures
References
- Wu F et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269, doi:10.1038/s41586-020-2008-3 (2020).
- Zhou P et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273, doi:10.1038/s41586-020-2012-7 (2020).
- Holshue ML et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 382, 929–936, doi:10.1056/NEJMoa2001191 (2020).
- Li Q et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med, doi:10.1056/NEJMoa2001316 (2020).
- Zhu N et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 382, 727–733, doi:10.1056/NEJMoa2001017 (2020).
- Chen N et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513, doi:10.1016/S0140-6736(20)30211-7 (2020).
- Huang C et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506, doi:10.1016/S0140-6736(20)30183-5 (2020).
- Chan JF et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514–523, doi:10.1016/S0140-6736(20)30154-9 (2020).
- Chandrashekar A et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science, doi:10.1126/science.abc4776 (2020).
- Yu J et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science, doi:10.1126/science.abc6284 (2020).
- Abbink P et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81, 4654–4663, doi:JVI.02696–06 [pii] 10.1128/JVI.02696-06 (2007).
- Alharbi NK et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine 35, 3780–3788, doi:10.1016/j.vaccine.2017.05.032 (2017).
- Kirchdoerfer RN et al. Pre-fusion structure of a human coronavirus spike protein. Nature 531, 118–121, doi:10.1038/nature17200 (2016).
- Pallesen J et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A 114, E7348-E7357, doi:10.1073/pnas.1707304114 (2017).
- Wrapp D et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263, doi:10.1126/science.abb2507 (2020).
- Yang ZY et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561–564, doi:10.1038/nature02463 (2004).
- Scobey T et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 110, 16157–16162, doi:10.1073/pnas.1311542110 (2013).
- Yount B et al. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 100, 12995–13000, doi:10.1073/pnas.1735582100 (2003).
- Chung AW et al. Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. Cell 163, 988–998, doi:10.1016/j.cell.2015.10.027 (2015).
- Wolfel R et al. Virological assessment of hospitalized patients with COVID-2019. Nature, doi:10.1038/s41586-020-2196-x (2020).
- Gao Q et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science, doi:10.1126/science.abc1932 (2020).
- Abbink P et al. Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci Transl Med 9, doi:10.1126/scitranslmed.aao4163 (2017).
- Abbink P et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129–1132, doi:10.1126/science.aah6157 (2016).
- Cox F et al. Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge. PLoS ONE 13, e0202820, doi:10.1371/journal.pone.0202820 (2018).
- Barouch DH et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13–19). Lancet 392, 232–243, doi:10.1016/S0140-6736(18)31364-3 (2018).
- Barouch DH et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 349, 320–324, doi:10.1126/science.aab3886 (2015).
- Baden LR et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 207, 240–247, doi:10.1093/infdis/jis670 (2013).
- Barouch DH et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29, 5203–5209, doi:10.1016/j.vaccine.2011.05.025 (2011).
- Graham BS Rapid COVID-19 vaccine development. Science, doi:10.1126/science.abb8923 (2020).
- Brown EP et al. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. J Immunol Methods 443, 33–44, doi:10.1016/j.jim.2017.01.010 (2017).
- Ackerman ME et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 366, 8–19, doi:10.1016/j.jim.2010.12.016 (2011).
- Lu LL et al. A Functional Role for Antibodies in Tuberculosis. Cell 167, 433–443 e414, doi:10.1016/j.cell.2016.08.072 (2016).
- Fischinger S et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J Immunol Methods 473, 112630, doi:10.1016/j.jim.2019.07.002 (2019).
Source: PubMed